KPMG has appointed Martin Rohrbach as the new Head of Life Sciences. In this capacity he will coordinate the full range of market activities for this key sector which comprises pharmaceuticals, biotechnology, medical research and diagnostics as well as MedTech.
KPMG has appointed Martin Rohrbach (43), Swiss certified accountant, as the new Head of Life Sciences. In this capacity he will coordinate all of KPMG Switzerland’s market activities in the areas of pharmaceuticals, biotechnology, medical research and diagnostics as well as MedTech. He is succeeding Erik Willems who spent the past few years successfully building up and developing this key sector.
"The life sciences industry needs new business models in order to find answers to megatrends such as demographic change, digitization and the accelerating pace at which client needs are changing. Not only that, but the industry also has to help resolve other key issues concerning the future of the healthcare system," explains Martin Rohrbach. These include developing integrated approaches toward improving the effectiveness of research and development, increasing the flexibility of procurement chains and ensuring greater tax transparency as well as tackling challenges related to digitization.
Martin Rohrbach has been working at KPMG since 1998. Prior to that, this passionate alpinist and amateur photographer held several different posts abroad, some of which with a focus on capital market transactions. A trained banker, he became familiar with the life sciences sector through years of experience in consulting companies of varying sizes.
© 2017 KPMG Holding AG is a member of the KPMG network of independent firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss legal entity. All rights reserved.